{"title":"神经生长因子治疗阿尔茨海默病计划临床试验的基本原理。","authors":"F Hefti, L S Schneider","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>A large number of experimental studies on animals suggest that intraventricular administration of NGF to Alzheimer patients may attenuate the degeneration of cholinergic neurons and the behavioral consequences associated with the cholinergic deficits. Based on these findings clinical trials with NGF seem justified, if potential detrimental effects are ruled out. Once NGF administration is proven effective it will be possible to develop alternative ways of NGF administration.</p>","PeriodicalId":77773,"journal":{"name":"Psychiatric developments","volume":"7 4","pages":"297-315"},"PeriodicalIF":0.0000,"publicationDate":"1989-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Rationale for the planned clinical trials with nerve growth factor in Alzheimer's disease.\",\"authors\":\"F Hefti, L S Schneider\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>A large number of experimental studies on animals suggest that intraventricular administration of NGF to Alzheimer patients may attenuate the degeneration of cholinergic neurons and the behavioral consequences associated with the cholinergic deficits. Based on these findings clinical trials with NGF seem justified, if potential detrimental effects are ruled out. Once NGF administration is proven effective it will be possible to develop alternative ways of NGF administration.</p>\",\"PeriodicalId\":77773,\"journal\":{\"name\":\"Psychiatric developments\",\"volume\":\"7 4\",\"pages\":\"297-315\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"1989-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Psychiatric developments\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Psychiatric developments","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Rationale for the planned clinical trials with nerve growth factor in Alzheimer's disease.
A large number of experimental studies on animals suggest that intraventricular administration of NGF to Alzheimer patients may attenuate the degeneration of cholinergic neurons and the behavioral consequences associated with the cholinergic deficits. Based on these findings clinical trials with NGF seem justified, if potential detrimental effects are ruled out. Once NGF administration is proven effective it will be possible to develop alternative ways of NGF administration.
分享
京公网安备 11010802042870号
京ICP备2023020795号-1
求助内容：
应助结果提醒方式：
扫码关注我们
